Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA retrospective study of tirabrutinib in relapsed or refractory PCNSL
jRCT1021230006Active, not recruiting
- Sponsor
- Kyorin University
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tirabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Kyorin University. Primary endpoint: Overall Survival. Started Apr 2023; status: active, not recruiting.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on jRCT1021230006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1021230006.